Insmed is a biopharmaceutical company based in Bridgewater, New Jersey, focusing on therapies for rare diseases, employing 912 staff. Its key products include ARIKAYCE, brensocatib, and TPIP for various lung diseases.
Roger Adsett sold 10,686 shares of INSM on 16 June at $99.32 per share, worth a total of $1.1M. They now own 134,823 INSM shares, or a 8% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
